MX393612B - Vacuna contra viruela para tratamiento del cancer. - Google Patents

Vacuna contra viruela para tratamiento del cancer.

Info

Publication number
MX393612B
MX393612B MX2018001755A MX2018001755A MX393612B MX 393612 B MX393612 B MX 393612B MX 2018001755 A MX2018001755 A MX 2018001755A MX 2018001755 A MX2018001755 A MX 2018001755A MX 393612 B MX393612 B MX 393612B
Authority
MX
Mexico
Prior art keywords
cancer treatment
smallpox vaccine
compositions
disclosed
methods
Prior art date
Application number
MX2018001755A
Other languages
English (en)
Other versions
MX2018001755A (es
Inventor
Aladar Szalay
Boris Minev
Original Assignee
Calidi Biotherapeutics Nevada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calidi Biotherapeutics Nevada Inc filed Critical Calidi Biotherapeutics Nevada Inc
Publication of MX2018001755A publication Critical patent/MX2018001755A/es
Publication of MX393612B publication Critical patent/MX393612B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación para usarse en el tratamiento de un tumor sólido o malignidad hematológica en un sujeto, en donde la combinación comprende: a) células estromales adiposas; y b) un virus oncolítico, que es un virus vaccinia.
MX2018001755A 2015-08-11 2016-08-11 Vacuna contra viruela para tratamiento del cancer. MX393612B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562203835P 2015-08-11 2015-08-11
US201562216292P 2015-09-09 2015-09-09
US201662317226P 2016-04-01 2016-04-01
PCT/US2016/046647 WO2017027757A2 (en) 2015-08-11 2016-08-11 Smallpox vaccine for cancer treatment

Publications (2)

Publication Number Publication Date
MX2018001755A MX2018001755A (es) 2018-08-01
MX393612B true MX393612B (es) 2025-03-24

Family

ID=56787706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001755A MX393612B (es) 2015-08-11 2016-08-11 Vacuna contra viruela para tratamiento del cancer.

Country Status (10)

Country Link
US (5) US10105436B2 (es)
EP (1) EP3334456A2 (es)
JP (1) JP6788663B2 (es)
KR (1) KR102201147B1 (es)
CN (2) CN108135996B (es)
CA (1) CA3004891C (es)
EA (1) EA201800148A1 (es)
HK (1) HK1248588A1 (es)
MX (1) MX393612B (es)
WO (1) WO2017027757A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732211A (en) 2014-10-24 2020-04-24 Calidi Biotherapeutics Inc Combination immunotherapy approach for treatment of cancer
JP6788663B2 (ja) 2015-08-11 2020-11-25 カリディ・バイオセラピューティクス・インコーポレイテッドＣａｌｉｄｉ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 癌処置のための天然痘ワクチン
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
CA3083158A1 (en) 2017-11-24 2019-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for treating cancers
CN112261951A (zh) * 2018-05-02 2021-01-22 通尼克斯制药控股有限公司 包含合成嵌合痘苗病毒的干细胞及其使用方法
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3876951A1 (en) * 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
CN114401740A (zh) * 2019-05-30 2022-04-26 伊美诺路克斯国际公司 痘病毒与自体诱导性多能干细胞用于疫苗接种和疾病治疗的用途
CN114555103A (zh) * 2019-06-03 2022-05-27 伊美诺路克斯国际公司 用于治疗疾病的天花疫苗和干细胞
US11110165B2 (en) 2019-10-10 2021-09-07 Ricardo Rosales Ledezma Therapeutic vaccine for the treatment of papillomavirus lesions
WO2021230704A1 (ko) * 2020-05-15 2021-11-18 서울대학교 산학협력단 지방조직에서 분리된 기질혈관분획의 수지상세포의 활성화 기능을 이용한 면역 반응 증진용 조성물
KR20220054225A (ko) * 2020-10-23 2022-05-02 에스케이바이오사이언스(주) 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트
CN119562825A (zh) * 2022-04-22 2025-03-04 Sk生物科学株式会社 用于减小靶组织的尺寸或体积的组合物或者包含该组合物的药盒

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010144A1 (en) 1994-04-29 2002-01-24 Robert Sobol Enhancing the sensitivity of tumor cells to therapies
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
CN101875919A (zh) 2004-11-12 2010-11-03 拜耳先灵医药股份有限公司 重组新城疫病毒
WO2007147600A2 (en) 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008052054A2 (en) 2006-10-24 2008-05-02 University Of South Alabama Synergism between activated immune cells and conventional cancer therapies
US8445275B2 (en) 2007-04-27 2013-05-21 Bavarian Nordic A/S Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF)
EP2173368A1 (en) 2007-07-18 2010-04-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
US20110171219A1 (en) 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
SG175127A1 (en) 2009-04-13 2011-11-28 Apceth Gmbh & Co Kg Engineered mesenchymal stem cells and method of using same to treat tumors
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
US20110027239A1 (en) 2009-07-29 2011-02-03 Tissue Genesis, Inc. Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
WO2011070974A1 (ja) 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
WO2012051210A2 (en) 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
US8859256B2 (en) * 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
US20150190505A1 (en) 2012-07-30 2015-07-09 Alex Wah Hin Yeung Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
NZ732211A (en) 2014-10-24 2020-04-24 Calidi Biotherapeutics Inc Combination immunotherapy approach for treatment of cancer
WO2016149559A1 (en) 2015-03-18 2016-09-22 Aladar Szalay Virotherapy with an antibody combination
JP6788663B2 (ja) 2015-08-11 2020-11-25 カリディ・バイオセラピューティクス・インコーポレイテッドＣａｌｉｄｉ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 癌処置のための天然痘ワクチン
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
AU2019282239B2 (en) 2018-06-04 2024-06-06 Calidi Biotherapeutics (Nevada), Inc. Cell-based vehicles for potentiation of viral therapy
EP3876951A1 (en) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
CN114555103A (zh) 2019-06-03 2022-05-27 伊美诺路克斯国际公司 用于治疗疾病的天花疫苗和干细胞

Also Published As

Publication number Publication date
HK1248588A1 (zh) 2018-10-19
MX2018001755A (es) 2018-08-01
JP2018527344A (ja) 2018-09-20
WO2017027757A3 (en) 2017-03-23
US20180326048A1 (en) 2018-11-15
US11607450B2 (en) 2023-03-21
US20240335530A1 (en) 2024-10-10
US20170043010A1 (en) 2017-02-16
CN108135996B (zh) 2022-06-21
EP3334456A2 (en) 2018-06-20
KR102201147B1 (ko) 2021-01-11
US10105436B2 (en) 2018-10-23
US20230173062A1 (en) 2023-06-08
KR20180042284A (ko) 2018-04-25
US10857225B2 (en) 2020-12-08
CA3004891A1 (en) 2017-02-16
US20210046178A1 (en) 2021-02-18
CN115212301A (zh) 2022-10-21
JP6788663B2 (ja) 2020-11-25
EA201800148A1 (ru) 2019-01-31
US12036278B2 (en) 2024-07-16
WO2017027757A2 (en) 2017-02-16
CN108135996A (zh) 2018-06-08
CA3004891C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
IL297418B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
ZA202004557B (en) Modulatory polynucleotides
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2023010042A (es) Polinucleotidos moduladores.
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
EA201790737A1 (ru) Комбинированная терапия
MX385845B (es) Usos y composiciones de la flagelina
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
GB2541571A (en) Pharmaceutical compositions
EA201991997A1 (ru) Комбинированная терапия
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
TW201613587A (en) Medical treatments based on anamorelin
EA201891287A1 (ru) Вакцинация с использованием альфа 3-домена mica/b для лечения рака
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
PH12016501838A1 (en) Compounds and their methods of use
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985
MX2019002566A (es) Inmunoterapia para poliomavirus.
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии
EA201992022A1 (ru) Терапевтическая рнк